Skip to content
D2M Biotherapeutics
  • About
    • Overview
    • Our Team
    • Partnerships
  • Platform
  • Pipeline
  • News
  • Careers
  • Contact Us
D2M Biotherapeutics
  • About
    • Overview
    • Our Team
    • Partnerships
  • Platform
  • Pipeline
  • News
  • Careers
  • Contact Us
  • We Are Transforming Innovative
    Therapies through Human
    Genetics Insights

    Data to Medicine (D2M) is transforming innovative drug discovery and development, harnessing the power of human genetic data. Through our INGENUITI platform, we are able to systematically identify disease causal genes in scale, and leverage human genetic insights to advance drugs with the potential for substantially improved clinical success. Our initial focus is on oncology and immune-inflammatory diseases with limited therapeutic options.

    Learn More
  • We Are Mining Disease
    Causal Genes From Vast
    Amounts of Genomic Data

    Data to Medicine (D2M) is transforming innovative drug discovery and development, harnessing the power of human genetic data. Through our INGENUITI platform, we are able to systematically identify disease causal genes in scale, and leverage human genetic insights to advance drugs with the potential for substantially improved clinical success. Our initial focus is on oncology and immune-inflammatory diseases with limited therapeutic options.

    Learn More
  • We Are Combating Cancer &
    Inflammatory Diseases Using
    Human Genetics-Validated Targets

    Data to Medicine (D2M) is transforming innovative drug discovery and development, harnessing the power of human genetic data. Through our INGENUITI platform, we are able to systematically identify disease causal genes in scale, and leverage human genetic insights to advance drugs with the potential for substantially improved clinical success. Our initial focus is on oncology and immune-inflammatory diseases with limited therapeutic options.

    Learn More

What We Stand For

Vision

Treating Disease Through Human Genetics Data-Driven Innovation

Mission

To Create Transformative Medicine by Unlocking the Potential of Human Genetics

Focus

Broadened Therapy for Cancer, and Immune-Inflammatory Diseases

Learn About Us
Harnessing Human Genetics

How We Do It

Our INGENUITI platform systematically identifies disease targets of significant value and confidence, leveraging insights from human genetics.

Discover the INGENUITI Platform

Our Team

Our team of seasoned geneticists and drug developers has built a pipeline of therapeutics for cancer and immune-inflammatory diseases. Our goal is to substantially improve clinical success, ultimately delivering revolutionary medicines to patients in need.

Meet Our Team

Latest Happenings

Press Releases

D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors

Natick, Mass., April 19, 2024 -- D2M Biotherapeutics, Inc. (D2M),...
Read More
High-tech Immunotherapeutics
Press Releases

D2M Biotherapeutics DM919 Investigational New Drug Application Approved by China’s National Medical Products Administration

Natick, Mass., April 1st, 2024 -- D2M Biotherapeutics Inc (D2M),...
Read More
Genetic Sequence Pipette
Press Releases

DM919 Receives FDA Clearance of IND Application to Treat Solid Tumors

D2M Biotherapeutics Announces FDA Clearance of Investigational New Drug (IND)Application...
Read More
Our Latest News
Want to Work With Us?

Contact Us for Partnership Inquiries

Let’s Make Medicine

© 2024 D2M Biotherapeutics  |  Privacy Policy

  • About
    • Our Team
    • Partnerships
  • Platform
  • Pipeline
  • News
  • Careers
  • Contact